Ascend supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.
Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Acutus Medical, Inc. is an arrhythmia management company that specializes in developing medical technologies for diagnosing and treating complex cardiac arrhythmias. Founded in 2011 and based in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product offerings include advanced imaging and mapping systems, such as the AcQMap console and workstation, along with diagnostic catheters and therapeutic devices like ablation catheters and robotic navigation systems. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment of arrhythmias. The company collaborates with medical scientists and engineers in the U.S. and Europe to enhance its product development and provides solutions to hospitals and electrophysiologists globally.
Itamar Medical Ltd. is an Israeli company specializing in the research, development, marketing, and sale of non-invasive medical devices tailored for the cardiology sector. Founded in 1997 and headquartered in Caesarea, the company utilizes its proprietary Peripheral Arterial Tone (PAT) signal technology to create devices that assess various cardiovascular and respiratory conditions. Its primary products include the WatchPAT device, designed for home testing of sleep disorders such as obstructive sleep apnea, and the EndoPAT device, which is FDA-approved for evaluating endothelial function and the risk of coronary artery disease. Itamar Medical serves a global market, including the United States, Canada, Europe, and Asia, and has established partnerships to enhance the delivery of its home sleep apnea testing services.
Stelexis Therapeutics, LLC is focused on researching and developing therapies aimed at pre-cancerous stem cells. Established in 2017 and headquartered in New York, the company utilizes its proprietary drug discovery platform to identify stem and progenitor cells that contribute to the formation of primary and recurrent tumors. Stelexis aims to create cancer drugs that specifically target pre-cancerous events associated with both hematopoietic malignancies, such as acute myeloid leukemia, and solid tumors. By concentrating on the earliest definable pre-cancerous stem cells, the company seeks to enable healthcare providers to intervene early and prevent the progression of cancer.
PQ Bypass, Inc. is a medical device company based in Milpitas, California, focused on developing innovative solutions for peripheral vascular disease through minimally-invasive techniques. Founded in 2009, PQ Bypass specializes in products designed for the treatment of long-segment femoropopliteal disease, including the DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System. The company aims to transform the treatment landscape for peripheral artery disease by providing effective endovascular options. Its leadership team comprises experienced professionals with backgrounds in major medical device firms and successful startups, bringing a wealth of expertise to the development of its advanced medical technologies.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Cabaletta Bio is a clinical-stage biotechnology company dedicated to developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Utilizing its proprietary technology, the company focuses on chimeric autoantibody receptor (CAAR) T cells, which are engineered to selectively target and eliminate pathogenic B cells responsible for producing harmful autoantibodies while preserving healthy B cells. The company’s lead product candidate, DSG3-CAART, is currently undergoing a Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, a debilitating autoimmune skin disease, as well as Hemophilia A with Factor VIII alloantibodies. Cabaletta's pipeline also includes MuSK-CAART, aimed at treating certain patients with myasthenia gravis, and FVIII-CAART and DSG3/1-CAART, both in earlier stages of development for different autoimmune conditions. Founded in 2017 and headquartered in Philadelphia, Cabaletta Bio has established collaborations with the University of Pennsylvania and The Regents of the University of California to further its research efforts.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
NeoChord, Inc. is a medical technology company that specializes in developing devices to address degenerative mitral valve disease (DMR), a condition that can lead to serious complications such as atrial fibrillation and congestive heart failure. The company's flagship product is the NeoChord Artificial Chordae Delivery System, a disposable device designed to repair damaged heart chordae through a small incision while the heart continues to beat. This innovative approach allows for mitral valve repair to be performed via a 2 to 3-inch incision between the ribs, significantly less invasive than traditional methods that require larger incisions and the use of heart-lung machines. Founded in 2007, NeoChord is headquartered in St. Louis Park, Minnesota.
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.
Allogene Therapeutics is a clinical-stage biotechnology company focused on immuno-oncology, particularly the development of genetically engineered allogeneic T cell therapies for cancer treatment. The company is advancing a pipeline of allogeneic T cell product candidates that leverage validated gene editing and proprietary cell manufacturing technologies. Key offerings include UCART19, which targets relapsed or refractory acute lymphoblastic leukemia, alongside several preclinical allogeneic CAR T therapies aimed at various malignancies and autoimmune diseases. By using T cells derived from healthy donors, Allogene Therapeutics aims to provide off-the-shelf treatment options that enhance patient eligibility and scalability. The company seeks to redefine CAR T therapy through its innovative approaches, addressing conditions like lymphoma, leukemia, and solid tumors.
Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.
MedAvail operates as a technology-enabled pharmacy company that integrates automated pharmacy services within clinics and other healthcare settings using its proprietary technology. The company offers comprehensive services through its robotic dispensing platform, known as the MedAvail MedCenter, alongside home delivery options. Additionally, it runs SpotRx, a telehealth platform that facilitates remote pharmacist consultations through on-site dispensing kiosks, complemented by home delivery services. MedAvail is headquartered in Mississauga, Canada.
Appello Pharmaceuticals, Inc. is a preclinical-stage company based in Nashville, Tennessee, specializing in the development of innovative positive allosteric modulators of mGlu4. These compounds are being investigated for their potential in treating Parkinson’s disease. The company aims to advance its research to provide new therapeutic options for this neurological disorder.
Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.
Strata Oncology is a precision oncology company focused on enhancing cancer care through increased access to clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, Strata develops a comprehensive oncology platform that facilitates routine genomic testing and the efficient use of molecular data. Its offerings include The Strata Trial, a genomic testing protocol aimed at implementing enterprise-wide precision oncology; StrataNGS, a targeted assay for sequencing DNA and RNA from biopsy samples; and StrataPOINT, which integrates electronic medical record data with molecular profiling to ensure eligible patients are tested and considered for precision trials. Additionally, the company manages Strata Partnered Trials, a collection of pharmaceutical-sponsored protocols linked to specific biomarkers, and operates The Strata Lab, a cancer sequencing facility. Through its collaborative network of cancer centers, Strata is dedicated to advancing precision medicine for patients with cancer, ultimately providing actionable insights for healthcare providers.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, particularly opioid addiction. Founded in 2012 and based in Plymouth Meeting, Pennsylvania, Braeburn aims to address the significant challenges posed by opioid use disorder, a chronic condition that leads to structural and functional changes in the brain. The company's lead product is BRIXADI, an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe opioid use disorder. Braeburn is dedicated to advancing next-generation therapies that offer individualized dosing regimens and various delivery options, thereby providing effective solutions for patients, healthcare providers, and society at large.
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the company partners with health plans and health systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. Quartet's platform facilitates access to suitable mental health care tailored to individual preferences and clinical needs, ensuring that care is compatible with patients' insurance plans. By connecting physicians, mental health providers, and insurance companies, Quartet seeks to improve the overall health of patients while also reducing healthcare costs.
Johns Hopkins University is a private research university located in Baltimore, Maryland, founded in 1876 with a significant philanthropic gift from its namesake, Johns Hopkins. Recognized as the first research university in the United States, it has played a pivotal role in transforming higher education by combining teaching and research. The university is renowned for its research output, leading U.S. institutions in annual research and development expenditures, with nearly $2.5 billion spent in fiscal year 2016 alone. Johns Hopkins offers a wide range of graduate and undergraduate programs and has additional campuses in Italy, China, and Washington, D.C. The university manages an endowment fund that supports various academic initiatives, including scholarships and research programs, with a notable focus on venture capital within its investment strategy. Consistently ranked among the top universities globally, Johns Hopkins continues to uphold its commitment to academic excellence and innovation.
Conventus Orthopaedics provides a range of orthopedic and sports medicine services. The physicians specialize in orthopedic surgery, reconstructive surgery, spine surgery, joint replacement, sports medicine, physical therapy, and operative care of fractures, arthritis, strains, sprains, and sports-related injuries. Conventus was formed by a team of medical professionals with the sole purpose of creating less invasive ways to treat challenging periarticular fractures. By leveraging advanced nitinol technology, the Conventus team has developed a platform technology that provides robust fixation and creates reliable repairs. The company was incorporated in 2009 and is based in Maple Grove, Minnesota.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions.
The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.
Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.
Chondrial Therapeutics LLC is a clinical-stage biotechnology company based in Indianapolis, Indiana, founded in 2013. The company specializes in discovering and developing orphan drugs aimed at treating rare mitochondrial diseases, with a particular focus on Friedreich’s Ataxia. Through its commitment to scientific research, Chondrial Therapeutics seeks to advance innovative therapies for patients affected by these challenging conditions.
Vensun Pharmaceuticals, Inc. is a pharmaceutical company based in Yardley, Pennsylvania, focused on developing a diverse portfolio of generic prescription products across various therapeutic categories and dosage forms. Established in 2011, Vensun actively collaborates with strategic partners both domestically and internationally to co-develop its products. The company has filed multiple Abbreviated New Drug Applications (ANDAs) with the FDA and currently has over 30 products in active development. Vensun is also seeking further partnerships, strategic alliances, and product acquisitions to expand its development portfolio, aiming to provide enhanced pharmaceutical options for clinicians and healthcare professionals in the U.S. generic market.
ConcertoCare provides healthcare services primarily to dual-eligible patients enrolled in Medicare and Medicaid, as well as those with complex medical needs. The company focuses on addressing critical vulnerabilities faced by these patients and health plans by offering personalized primary care, chronic condition management, and support for transitions between various care settings. Additionally, ConcertoCare delivers medical, social, and logistical assistance to enhance patient outcomes. Founded in 2004 and based in Aliso Viejo, California, the company operates care centers in locations including Renton, Washington, and several cities in Michigan. The name Concerto reflects its holistic approach to healthcare, emphasizing collaboration among patients, providers, and health plans to ensure coordinated care that respects the dignity and health of each individual.
SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions.
The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company's key products include Rhopressa, a once-daily eye drop that lowers elevated intraocular pressure in glaucoma patients, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for treating open-angle glaucoma and ocular hypertension. Additionally, Aerie is advancing its clinical-stage product AVX-012 for dry eye and developing sustained-release implants AR-1105 and AR-13503 for retinal diseases. Established in 2005, Aerie is headquartered in Durham, North Carolina, with research facilities in Research Triangle Park. The company has also formed a collaborative research and development agreement with DSM.
Nuo Therapeutics is a biotechnology company that develops, sells, and licenses regenerative biological therapies to primarily address the areas of wound care, inflammation, and angiogenesis. The Company markets the AutoloGel System, a device for the production of platelet rich plasma gel derived from the patient's own blood. The AutoloGel System is cleared by the United States Food and Drug Administration for use on a variety of exuding wounds.
Nuo Therapeutics is headquartered in Gaithersburg, Maryland.
Alphatec Spine, Inc., a medical technology company based in Carlsbad, California, specializes in designing, developing, and manufacturing products for the surgical treatment of spinal disorders. The company's offerings include a range of spinal fixation systems, minimally invasive surgical solutions, and interbody fusion devices, aimed at addressing conditions affecting the aging spine and other spinal pathologies. Key products include the Invictus Spinal Fixation System, various anterior and posterior lumbar interbody fusion systems, and biologics such as demineralized bone matrices and scaffolds. Alphatec Spine also markets its innovations, including access systems and surgical instrumentation, through a direct sales force in several countries and a network of independent distributors globally. Founded in 1990, the company has expanded its reach to international markets, including Europe and Asia, providing advanced technologies to enhance surgical outcomes for patients with spinal conditions.
MannKind Corporation is a biopharmaceutical company specializing in the development and commercialization of inhaled therapeutic products aimed at treating diabetes and pulmonary arterial hypertension. The company's flagship product, Afrezza, is an inhaled insulin designed to enhance glycemic control in adults with diabetes. Additionally, MannKind has a collaboration with United Therapeutics Corporation to develop a dry powder formulation of treprostinil for pulmonary arterial hypertension. Founded in 1991 and headquartered in Westlake Village, California, MannKind continues to focus on innovative solutions for patients with chronic conditions.
Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.
Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of Huntington's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.
Private Equity Round in 2010
Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The company's lead product candidate, Marqibo(R), potentially treats acute lymphoblastic leukemia and lymphomas.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development of innovative medicines targeting various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. The company's pipeline features several investigational drugs, including Etrasimod, currently in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn's disease, along with studies for atopic dermatitis. Additionally, Olorinab is in Phase IIb trials for abdominal pain associated with irritable bowel syndrome, while APD418 is in early Phase I trials for acute heart failure. Ralinepag is also undergoing Phase III trials for pulmonary arterial hypertension. Arena Pharmaceuticals has established collaboration agreements with various pharmaceutical companies, enhancing its research and development efforts. The company was founded in 1997 and has made significant strides in the biotechnology field, particularly in targeting G-protein-coupled receptors.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Their technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Their miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
Arena Pharmaceuticals, Inc. is a biopharmaceutical company based in San Diego, California, specializing in the development of innovative medicines targeting various diseases, including cardiovascular, central nervous system, inflammatory, and metabolic disorders. The company's pipeline features several investigational drugs, including Etrasimod, currently in Phase III trials for ulcerative colitis and Phase IIb/III for Crohn's disease, along with studies for atopic dermatitis. Additionally, Olorinab is in Phase IIb trials for abdominal pain associated with irritable bowel syndrome, while APD418 is in early Phase I trials for acute heart failure. Ralinepag is also undergoing Phase III trials for pulmonary arterial hypertension. Arena Pharmaceuticals has established collaboration agreements with various pharmaceutical companies, enhancing its research and development efforts. The company was founded in 1997 and has made significant strides in the biotechnology field, particularly in targeting G-protein-coupled receptors.
NitroMed is an emerging pharmaceutical company that discovers, develops and seeks to commercialize proprietary pharmaceuticals based on the therapeutic benefits of the naturally-occurring molecule nitric oxide. NitroMed is conducting a late-stage confirmatory trial of our lead nitric oxide-enhancing drug, BiDil, for the treatment of heart failure in African Americans.
Pacific Biosciences designs, develops, and manufactures advanced sequencing systems that address complex genetic challenges. Utilizing single molecule real-time (SMRT) sequencing technology, it enables the real-time detection of biological processes at the single-molecule level. The company offers products such as the PacBio RS II and Sequel Systems, which are capable of conducting, monitoring, and analyzing biochemical reactions in real time. In addition to sequencing systems, Pacific Biosciences provides consumables like SMRT cells and various reagent kits essential for template preparation, binding, and sequencing. Its diverse customer base includes research institutions, commercial laboratories, genome centers, and various sectors such as pharmaceuticals and agriculture. The company markets its products through a direct sales force in North America and Europe, along with distribution partners in Asia, the Middle East, and Latin America. Founded in 2000, Pacific Biosciences is headquartered in Menlo Park, California.
Tengion is a clinical-stage biotechnology company focused on the development of neo-organs and neo-tissues derived from a patient's own cells. The company has successfully completed two Phase 2 clinical trials in the United States for its Neo-Bladder Augment, which aims to assist children with neurogenic bladder resulting from spina bifida and adults with similar conditions due to spinal cord injuries. An earlier academic study on a urinary Neo-Bladder Augment was published in The Lancet in April 2006, highlighting its potential benefits. Tengion also holds an effective investigational new drug application for its Neo-Urinary Conduit and anticipates initiating a Phase 1 clinical trial for bladder cancer patients requiring bladder removal.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
Novare Surgical Systems, Inc. develops, manufactures, and markets devices for minimally invasive surgery. It offers motion hand-held laparoscopic instruments, which includes graspers, dissectors, cautery, and needle holders. The company's products are used in acid reflux treatment, adrenal gland removal, colon resection, gastric bypass, hysterectomy, lung lobe removal, ovary removal, prostate removal, achalasia treatment, appendix removal, gall bladder removal, hernia repair, lymph node extraction, kidney removal, pelvic mass removal, and spleen removal procedures. It provides its products through its sales representatives in the United States, Austria, Belgium, Canada, Denmark, Greece, Israel, Italy, Korea, Sweden, Switzerland, and Turkey. Novare Surgical Systems, Inc. was founded in 1999 and is headquartered in Cupertino, California.